![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
950kB | |
|
PDF (Supplementary Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
453kB |
| Item Type: | Article |
|---|---|
| Title: | Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina |
| Creators Name: | Contentti, E.C. and Lopez, P.A. and Pettinicchi, J.P. and Criniti, J. and Pappolla, A. and Miguez, J. and Patrucco, L. and Carnero Contentti, E. and Liwacki, S. and Tkachuk, V. and Balbuena, M.E. and Vrech, C. and Deri, N. and Correale, J. and Marrodan, M. and Ysrraelit, M.C. and Leguizamon, F. and Luetic, G. and Menichini, M.L. and Tavolini, D. and Mainella, C. and Zanga, G. and Burgos, M. and Hryb, J. and Barboza, A. and Lazaro, L. and Alonso, R. and Liguori, N.F. and Nadur, D. and Chercoff, A. and Alonso Serena, M. and Caride, A. and Paul, F. and Rojas, J.I. |
| Abstract: | We aimed to examine treatment interventions implemented in patients experiencing neuromyelitis optica spectrum disorders (NMOSD) attacks (frequency, types, and response). METHODS: Retrospective study. Data on patient demographic, clinical and radiological findings, and administered treatments were collected. Remission status (complete [CR], partial [PR], no remission [NR]), based on changes in the EDSS score was evaluated before treatment, during attack, and at 6 months. CR was analyzed with a generalized estimating equations (GEEs) model. RESULTS: A total of 131 patients (120 NMOSD and 11 myelin oligodendrocyte glycoprotein-antibody-associated diseases [MOGAD]), experiencing 262 NMOSD-related attacks and receiving 270 treatments were included. High-dose steroids (81.4%) was the most frequent treatment followed by plasmapheresis (15.5%). CR from attacks was observed in 47% (105/223) of all treated patients. During the first attack, we observed CR:71.2%, PR:16.3% and NR:12.5% after the first course of treatment. For second, third, fourth, and fifth attacks, CR was observed in 31.1%, 10.7%, 27.3%, and 33.3%, respectively. Remission rates were higher for optic neuritis vs. myelitis (p < 0.001). Predictor of CR in multivariate GEE analysis was age in both NMOSD (OR = 2.27, p = 0.002) and MOGAD (OR = 1.53, p = 0.03). CONCLUSIONS: This study suggests individualization of treatment according to age and attack manifestation. The outcome of attacks was generally poor. |
| Keywords: | Neuromyelitis Optica Spectrum Disorders, Attacks, Disability, Treatment Response, Latin America |
| Source: | Multiple Sclerosis Journal Experimental Translational and Clinical |
| ISSN: | 2055-2173 |
| Publisher: | Sage Publications |
| Volume: | 7 |
| Number: | 3 |
| Page Range: | 20552173211032334 |
| Date: | 1 July 2021 |
| Official Publication: | https://doi.org/10.1177/20552173211032334 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
